Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Silo Pharma (SILO) EPS (Weighted Average and Diluted) (2019 - 2025)

Silo Pharma's EPS (Weighted Average and Diluted) history spans 7 years, with the latest figure at -$0.09 for Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 52.63% year-over-year to -$0.09; the TTM value through Sep 2025 reached -$0.91, up 8.08%, while the annual FY2024 figure was -$1.19, 0.85% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q3 2025 was -$0.09 at Silo Pharma, up from -$0.18 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $3.2 in Q3 2021 and bottomed at -$0.58 in Q4 2022.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.28 (2024), against an average of -$0.01.
  • The largest annual shift saw EPS (Weighted Average and Diluted) surged 30147.45% in 2021 before it plummeted 6818.54% in 2022.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $1.39 in 2021, then crashed by 141.73% to -$0.58 in 2022, then soared by 41.13% to -$0.34 in 2023, then decreased by 20.08% to -$0.41 in 2024, then surged by 78.05% to -$0.09 in 2025.
  • Per Business Quant, the three most recent readings for SILO's EPS (Weighted Average and Diluted) are -$0.09 (Q3 2025), -$0.18 (Q2 2025), and -$0.23 (Q1 2025).